Paul Reider spent many years developing drugs for the pharmaceutical industry, working with top chemists to combat some of humanity's worst diseases, such as HIV. Nonetheless, the optimism and open-mindedness of the Princeton University have been very important to me. "
" It's what they do not know that makes them wonderful, "said Reider, lecturer with the rank of professor in the Department of Chemistry. "They are the most uninhibited and outspoken students I deal with. They are so much smarter than I am and they are completely uninhibited with their questions."
For three years, Reider has taught the freshman seminar "Drug Discovery: From Snake Venoms to Medicines," which is formally designated the Shelly and Michael Kassen '76 Freshman Seminar in the Life Sciences. Above, Reider hosts a discussion on the ethics of drug delivery at his home April 20. Above, Reider hosts a discussion on the ethics of drug delivery at his home April 20. Reider, who led the production of the landmark HIV drug Crixivan in the 1990s, told the students during the lesson that they will likely face public health crisis in their lives: "You, too, will live through what I lived through." < / p>
As a semester-long project, the students form teams that work towards a real solution to a problem associated with an ailment. Alzheimer's disease, amyotrophic lateral sclerosis (ALS), autism and chikungunya, the viral mosquito-borne infection that causes severe fever and pain.
Zhang works in the ALS group, which causes muscular degeneration and is the impetus behind the popular Ice Bucket Challenge. The group is working on methods of identifying genetic and non-genetic causes of the disorder. The project - like the class in general - has taught Zhang that for everything she knows about a disease, there seems to be a lot more that she did not know.
"There are so many critical questions about ALS that is not answered. It's frightening how much we do not know about it despite how much publicity it's had, "Zhang said. During the lesson at Reider's home, the students watched in 1995. "It's not going to be a problem with one solution and that's the biggest thing I've learned from this class - disease is complicated."
news segment featuring Reider about a controversial lottery set up to distribute Crixivan while it was still in clinical trials. Afterward, the students discussed how they would efficiently and ethically distribute a drug with a limited supply of high demand.
Reider spent decades immersed in that complexity. I have worked for 22 years in drug development and production for pharmaceutical giant Merck and Co. Inc. before retiring in 2002. I went to work at biotechnology company AMGEN before joining Princeton's faculty in 2008. In 2011, I received the National Academy of Sciences Award for Chemistry in Service to Society for his work developing drug treatments for various diseases, including HIV. He led the manufacturing process for Merck's landmark drug Crixivan, an antiretroviral released in 1996 and still used globally that made AIDS treatment far more manageable.
"People do not understand why drugs come from or why they're important," Reider said. "This class teaches them about the diversity of opinions, what the issues are and really what the landscape is, the issues that need to be worked on."
For José Mazariegos, from near San Francisco, the issues of access and the cost of treatment stuck out. "I did not like the ring of that people are making a profit off humanity," he said. "Saving lives should be a big enough reward."
Skyline Theatre students are preparing songs dances and scenes for “Get Hype An Evening With Skyline Theatre.”
Mazariegos said that before taking Reider's seminar he never knew much about medicine other than how to get it. "I never understood the processes behind how much value is put on a drug," he said. "I feel like I was really lucky to get Paul as a freshman seminar teacher, especially since he has a lot of knowledge. He has a great job of introducing science material in a way that is not science heavy."
Reider hosts a dinner and class discussion at his house for the seminar. He said the dinner "essentially bridges a gap between teacher and student."
On April 20, seminar students gathered at Reider's house for dinner and discussion. "Reid said," Reid said, "Reid said," I do not know what to do. "Reider presented a 1995 segment from ABC's Nightline titled," Gambling for Time, " about a lottery Merck instated during the clinical-trial phase of Crixivan.
The lottery was criticized at the time for seeming too cavalier, Merck said it was the only way to distribute the drug fairly. During the class discussion, Reider said, "This was the proudest moment of the pharmaceutical industry - we all worked out together. "
Seyd, who had an interest in medicine in high school, said that knowing about diseases and treatment seems like "life preparedness," essential information for a person to have. Seyd said during the class discussion that she was impressed by the effectiveness of the AIDS activists featured in the Nightline piece. She wondered if the glut of information that exists in the era of the internet and social media would make such an effort less effective.
"I feel people get complacent because we get so much information," Seyd said. "You wonder how much effect an activist campaign would have."
Reider pointed out that drug-development process has slowed since the mid-1990s - more barriers exist among regulatory agencies, which are not as efficient, and pharmaceutical companies, which are more profit-driven, he said. If the Zika virus, for instance, became a crisis, developing and releasing a treatment would "move too slowly," he said.
Lilly Chadwick, of Nashville, Tennessee, said that as a consumer, she found what she learned about the regulatory process. "If you did not know anything about the industry, you'd think that there's a need for a scientist to eat with a drug," she said. "It was kind of uplifting that there's research the average population does not know about, but at the same time it's troubling that it takes years to approve drugs."
Chadwick works in the Alzheimer's disease group. They are coming up with a model procedure for developing diverse test trials and framing economic costs. Chadwick said the project teaches her skills she would be useful in a variety of fields. At the very least, it shows the range of factors that go into treating disease.
"The procedure behind finding a drug all seemed very arbitrary to me," Chadwick said. "But there are so many things going on that everyday public is not aware of."More news: Rosa 'Heritage' - Wikipedia, the free encyclopedia
More news: Pablo Neruda - New Odes Elementales - First Edition - Signed | Bauman Rare Books
More news: Bees swarm halts cricket match in South Africa